Umesh Kumar Agarwal’s Post

2023 was a record-breaking year! The overall drug pipeline expanded by 7.2%, to hit a new high of almost 23,000 drugs in development. So does this mean clear skies ahead? Find out in our Pharma Annual R&D Review. Full report out soon. #AnnualRDReport #ResearchAndDevelopment #PharmaTrends

Which drugs will lose patents in the coming years? A great overview by Joanna Sadowska, PhD, EMBA - many thanks for this superb work! Nearly 200 drugs are going off-patent in the near future These include at least 69 blockbusters (>$1B in annual sales) This could lead to over 49% revenue decline for major companies The pharmaceutical industry is staring down a major patent cliff, with more than $300B in sales at risk in coming years. Unlike the previous patent cliff, this one includes a fair number of biologics, making the transition to biosimilars highly relevant. Navigating this coming cliff will require a combination of innovation and strategy from the pharmaceutical industry. Who will be the biggest loser in the coming years? Check the graphic and comment. *The infographic represents US patent expiry and is not exhaustive of all off-patents. Sources: Pharma Voice, BioSpace, Statista Visit our Website: likeways.co.in #inspiration #health #hiring #networking #business #culture #strategy #fundraising #socialentrepreneurship #sales #travel #productivity #personalbranding #sustainability #jobinterviews #socialmedia #socialnetworking #innovation #management #technology #creativity #futurism

US Passes Biosecure Act — A Game Changer For Indian Pharma India’s CDMO sector, which currently holds just 2.7% of the global market, could see substantial growth. In a significant development for the global pharmaceutical industry, the US has enacted the Biosecure Act, which bans American companies from partnering with specific Chinese biotech firms. The ban targets major players like BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec, and WuXi Biologics, pushing US drugmakers to look towards alternative suppliers. Over the next 12-18 months, Indian companies anticipate a surge in orders from the US, including new pilot projects and higher requests for quote. #pharmaceutical #indianpharmaceutical #healthcare #pharmaceuticalindustry #pharmanews Source - NDTV Business

#biopharma week. Did you miss it? #japan pharma #clinicaltrials strategy. Given that clinical trials account for 37% of most pharma firms' R&D budget. Each delay during the trials can compound the cost associated with the potential #blockbuster drug in the making. Companies across the #pharmaceuticalindustry need strategies that enhance the savings potential while boosting the likelihood of winning the game, particularly in a sophisticated market such as Japan. #leadership #biotech #japanbusiness #japanesemarket #innovation #business #strategy

There has been a massive surge in demand for our services, which support the development and commercialisation of devices for use in diagnostics, drug delivery, biotech and pharma. #injectionmoulding #moulding #injection #iso9001 #iatf #inyecciondeplastico #mexico #klumex #nearshoring

Thoughts on this? >> Merck exercises option on one Kelun ADC, returns another as it tweaks broad deal >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma

2023 marked another record-breaking year! The overall drug pipeline expanded by 7.2%, reaching a new high of almost 23,000 drugs in development. Discover more essential insights in the new Pharma R&D Annual Review 2024. Download the full report today. https://ow.ly/gxuZ50RcwJk #PharmaRnD #AnnualReview #PharmaTrends

Excellent post and visual here from Joanna Sadowska, PhD, EMBAabout the "The Pharma Patent Cliff" Here's my point of view from a Leadership and Talent standpoint. The graphic is quite hard-hitting, in what could be a defining era for the pharma industry. Over the next decade, leading brands like Keytruda, Ozempic, and Dupixent will lose patent exclusivity, exposing $200B+ in annual sales to generic and biosimilar competition. For pharma companies facing these cliffs, the stakes are very, very high. To bounce back, they need visionary leadership that can: ➡️ Prioritize pipeline innovation to drive new revenues. ➡️ Redefine market access strategies for a more competitive landscape. ➡️ Build strategic alliances in generics, biosimilars, or emerging tech. But where there are challenges, obviously there is also opportunity when hiring leaders! The generics and biosimilars industry are on the precipice of a hiring boom (as is the CDMO industry) who are seeing an unprecedented opportunity to hire talent from large pharma. Will hiring from these companies work? Not always.... But hiring leaders with expertise in commercialization, regulatory strategy, and pricing models will be vital as these companies scale. So what for those large pharma firms - Retention becomes a big issue - HR and talent development take center stage. As the industry transforms (We're calling it the Big Pharma Reform aren't we Aidan Russell), The focus shifts to recruiting and retention - the ability to attract and retain high-performing leaders will determine whether companies stay competitive. The question I have - Does your talent strategy align with the new realities of the pharma landscape? I'd love to understand the thoughts from my network - on how pharma companies are going to have to approach hiring and keeping their best leaders during this transformative/Patent Cliff Era? #Pharma | #LeadershipSearch | #TalentStrategy | #Biosimilars

With many drugs going off patent and an unstable pharmaceutical landscape this year - coupled with numerous significant reorganisation. If you wonder:- 🧐What are the market trends and talent movement? 🤓What are the strategy and plan for innovative medicine? 🥸Who, what and why are they hiring? 🤫Am I getting a competitive package/ what is the salary benchmark for certain positions? Let’s catch up, build connection and discuss the market. Feel free to reach out so we can cross paths and speak more. [email protected] +65 6228 5385‬ (contactable via WhatsApp/ call) #exchangeinsights #pharmaceutical #markettrends

🚨💊 Curious which #generics will hit the market? Many big-name drugs are losing their #DrugPatents.🚨 📉 Nearly 200 drugs are set to go off-patent soon out of which 69+ blockbusters ($1B+ in annual sales) are affected 📉 Expect a 49%+ revenue decline for major companies 🔬The #PharmaceuticalIndustry is facing a $300B patent cliff in the next few years. Unlike past patent cliffs, this one includes biologics, making the shift to biosimilars more significant. #Innovation & strategy will be essential to navigate this challenge. 🔍 If you're looking for opportunities, now is the time to explore and get ready to step up!